¿Preguntas sobre el cáncer? 1-800-422-6237
  • Imprimir
  • Enviar por correo electrónico
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Cuadro 4. Regímenes quimioterapéuticos contemporáneos para niños y adolescentes con linfoma de Hodgkin

Nombre Fármacos Dosificación Ruta Días 
IV = intravenosa; O = oral.
COPP [41]Ciclofosfamida600 mg/m2IV1, 8
Vincristina (Oncovin)1,4 mg/m2IV1, 8
Procarbazina100 mg/m2O1–15
Prednisona40 mg/m2O1–15
COPDAC [41]Dacarbazina sustituida por procarbazina en COPP250 mg/m2IV1–3
OPPA [41]Vincristina (Oncovin)1,5 mg/m2IV1, 8, 15
Procarbazina100 mg/m2O1–15
Prednisona60 mg/m2O1–15
Doxorrubicina (Adriamycin)40 mg/m2IV1, 15
OEPA [41]Vincristina (Oncovin)1,5 mg/m2IV1, 8, 15
Etopósido125 mg/m2IV3–6
Prednisona60 mg/m2O1–15
Doxorrubicina (Adriamycin)40 mg/m2IV1, 15
ABVD [7]Doxorrubicina (Adriamycin)25 mg/m2IV1, 15
Bleomicina10 U/m2IV1, 15
Vinblastina6 mg/m2IV1, 15
Dacarbazina375 mg/m2IV1, 15
COPP/ABV [14]Ciclofosfamida600 mg/m2IV0
Vincristina (Oncovin)1,4 mg/m2IV0
Procarbazina100 mg/m2O0–6
Prednisona40 mg/m2O0–13
Doxorrubicina (Adriamycin)35 mg/m2IV7
Bleomicina10 U/m2IV7
Vinblastina6 mg/m2IV7
VAMP [42]Vinblastina6 mg/m2IV1, 15
Doxorrubicina (Adriamycin)25 mg/m2IV1, 15
Metotrexato20 mg/m2IV1, 15
Prednisona40 mg/m2O1–14
DBVE [43,44]Doxorrubicina25 mg/m2IV1, 15
Bleomicina10 U/m2IV1, 15
Vincristina (Oncovin)1,5 mg/m2IV1, 15
Etopósido100 mg/m2IV1–5
ABVE-PC [35]Doxorrubicina (Adriamycin)30 mg/m2IV0, 1
Bleomicina10 U/m2IV0, 7
Vincristina (Oncovin)1,4 mg/m2IV0, 7
Etopósido75 mg/m2IV0–4
Prednisona40 mg/m2O0–9
Ciclofosfamida800 mg/m2IV0
BEACOPP [45]Bleomicina10 U/m2IV7
Etopósido200 mg/m2IV0–2
Doxorrubicina (Adriamycin)35 mg/m2IV0
Ciclofosfamida1.200 mg/m2IV1, 8
Vincristina (Oncovin)2 mg/m2IV7
Prednisona40 mg/m2O0–13
Procarbazina100 mg/m2O0–6
CVP [46]Ciclofosfamida500 mg/m2IV1
Vinblastina6 mg/m2IV1,8
Prednisolona40 mg/m2PO1–8


  1. Bonadonna G, Santoro A: ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev 9 (1): 21-35, 1982.  [PUBMED Abstract]

  2. Nachman JB, Sposto R, Herzog P, et al.: Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 20 (18): 3765-71, 2002.  [PUBMED Abstract]

  3. Schwartz CL, Constine LS, Villaluna D, et al.: A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood 114 (10): 2051-9, 2009.  [PUBMED Abstract]

  4. Mauz-Körholz C, Hasenclever D, Dörffel W, et al.: Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 28 (23): 3680-6, 2010.  [PUBMED Abstract]

  5. Donaldson SS, Link MP, Weinstein HJ, et al.: Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol 25 (3): 332-7, 2007.  [PUBMED Abstract]

  6. Tebbi CK, Mendenhall N, London WB, et al.: Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study. Pediatr Blood Cancer 46 (2): 198-202, 2006.  [PUBMED Abstract]

  7. Tebbi CK, Mendenhall NP, London WB, et al.: Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer 59 (7): 1259-65, 2012.  [PUBMED Abstract]

  8. Kelly KM, Sposto R, Hutchinson R, et al.: BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood 117 (9): 2596-603, 2011.  [PUBMED Abstract]

  9. Shankar A, Hall GW, Gorde-Grosjean S, et al.: Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report. Eur J Cancer 48 (11): 1700-6, 2012.  [PUBMED Abstract]